Minimal change in structural, functional and inflammatory markers of lung disease in newborn screened infants with cystic fibrosis at one year

Authors: Davies, Gwyneth, Thia, Lena P, Stocks, Janet, Bush, Andrew, Hoo, Ah-Fong, Wade, Angie, Nguyen, The Thanh Diem, Brody, Alan S, Calder, Alistair, Klein, Nigel J, Carr, Siobhán B, Wallis, Colin, Suri, Ranjan, Pao, Caroline S, Ruiz, Gary, Balfour-Lynn, Ian M

Source: In Journal of Cystic Fibrosis November 2020 19(6):896-901

High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis

Authors: Al-Malky, Ghada, Dawson, Sally J., Sirimanna, Tony, Bagkeris, Emmanouil, Suri, Ranjan

Source: In Journal of Cystic Fibrosis March 2015 14(2):248-254

Body composition assessed by the 4-component model and association with lung function in 6–12-y-old children with cystic fibrosis

Authors: Williams, Jane E, Wells, Jonathan CK, Benden, Christian, Jaffe, Adam, Suri, Ranjan, Wilson, Catherine M, Fewtrell, Mary S

Source: In The American Journal of Clinical Nutrition December 2010 92(6):1332-1343

Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial

Authors: Suri, Ranjan, Metcalfe, Chris, Wallis, Colin, Bush, Andrew

Source: In Respiratory Medicine 2007 101(2):254-260

Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial.

Authors: Suri, Ranjan, Metcalfe, Christopher, Lees, Belinda

Source: Lancet; October 20 2001, Vol. 358 Issue 9290, p1316-1321, 6p

The Use of Human Deoxyribonuclease (rhDNase) in the Management of Cystic Fibrosis.

Authors: Suri, Ranjan¹

Source: BioDrugs. 2005, Vol. 19 Issue 3, p135-144. 10p.

Subject Terms: *DEOXYRIBONUCLEASES, *NUCLEASES, *CYSTIC fibrosis treatment, *GENETIC disorders, *LUNG diseases

Normal hearing in a child with the m.1555A>G mutation despite repeated exposure to aminoglycosides. Has the penetrance of this pharmacogenetic interaction been overestimated?

Authors: Al-Malky, Ghada, Suri, Ranjan, Sirimanna, Tony, Dawson, Sally J.

Source: In International Journal of Pediatric Otorhinolaryngology June 2014 78(6):969-973

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Azathioprine in the management of enteropathy in cystic fibrosis.

Authors: Hui-Leng Tan, Shah, Neil, Suri, Ranjan

Source: Journal of the Royal Society of Medicine (Supplement); Jul2011, Vol. 104 Issue 1, pS40-S43, 4p, 2 Color Photographs, 1 Black and White Photograph

Subject Terms: THERAPEUTIC use of antimetabolites, CYSTIC fibrosis, ENDOSCOPY, GASTROINTESTINAL diseases, EXAMINATION of the gastrointestinal system

Free Secretory Component from Cystic Fibrosis Sputa Displays the Cystic Fibrosis Glycosylation Phenotype.

Authors: Marshall, Lindsay J., Perks, Beatrice, Bodey, Kathleen, Suri, Ranjan, Bush, Andrew, Shute, Janis K.

Source: American Journal of Respiratory & Critical Care Medicine; 2004, Vol. 169 Issue 3, p399-406, 17p, 1 Chart, 8 Graphs

A cost-effectiveness analysis of rhDNase in children with cystic fibrosis.

Authors: Grieve, Richard¹, Thompson, Simon, Normand, Charles, Suri, Ranjan, Bush, Andrew, Wallis, Colin

Source: International Journal of Technology Assessment in Health Care; Jan2003, Vol. 19 Issue 1, p71-79, 9p

This result is not displayed to guests.
Login for full access.

Clinical Review: Cystic fibrosis.

Authors: Petrocheilou, Argyri, Suri, Ranjan

Source: GP: General Practitioner; 5/13/2011, p36, 1p